Investment Rating - The report maintains a "Recommended" rating for Shandong Pharmaceutical Glass [3][9] Core Views - The company is experiencing significant demand pressure, leading to a decline in revenue and net profit for 2025. Revenue is reported at 4.47 billion yuan, down 8.8% year-on-year, and net profit at 690 million yuan, down 26.9% year-on-year [9] - The report highlights that the company's core products are facing negative growth, particularly in the domestic market, while overseas sales show resilience. The inventory level has increased, indicating weak sales momentum [9] - The report anticipates a gradual recovery in demand and suggests that the company’s leading position in the molded bottle market remains solid, with a positive long-term growth outlook for the pharmaceutical packaging materials industry [9] Financial Forecasts - Revenue projections for 2026, 2027, and 2028 are 4.78 billion yuan, 5.19 billion yuan, and 5.64 billion yuan, respectively, with expected growth rates of 6.9%, 8.5%, and 8.6% [3][10] - Net profit forecasts for the same years are 797 million yuan, 900 million yuan, and 1.01 billion yuan, with growth rates of 15.6%, 12.9%, and 12.3% [3][10] - The report indicates a projected PE ratio of 16x for 2026, 14x for 2027, and 13x for 2028, suggesting the stock is currently undervalued [3][10]

Core Viewpoint - The company announced its performance for 2024 and Q1 2025, showing a modest revenue growth and significant improvement in profitability metrics, while also planning a substantial cash dividend for shareholders [1][4]. Revenue Performance - In 2024, the company's revenue is projected to be 51.3 billion, with a year-over-year (yoy) growth of 3%. For Q1 2025, revenue is expected to be 12.4 billion, reflecting a yoy decline of 2% [1]. - The revenue growth across various business segments in 2024 shows mixed results, with some segments like molded bottles and trade business experiencing growth, while others like ampoules and plastic bottles faced declines [2]. Profitability Improvement - The company's overall gross margin improved by 3.7 percentage points yoy to 31.7% in 2024, with specific segments like molded bottles and rubber stoppers showing notable improvements [3]. - The net profit margin for 2024 is expected to increase by 2.8 percentage points yoy to 18.4%, indicating a positive trend in profitability [3]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 4.1 billion for 2024, which represents a yoy increase of 55%, with a dividend payout ratio rising to 43.6% [1][4]. - The current share price corresponds to a price-to-earnings (PE) ratio of 14.6x for 2025, which is considered to be at a historically low valuation level [4]. Growth Outlook - Despite current demand pressures, the company is expected to achieve revenue growth of 6% to 11% from 2025 to 2027, with net profit also projected to grow at a similar rate [4]. - The company maintains a strong position in the molded bottle market, with resilient demand expected for pharmaceutical glass products, and is actively improving its product mix and expanding into overseas markets [4].